MedTrace Logo

Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting

NCT04570592 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2020-09-30

No results posted yet for this study

Summary

Intrathecal morphine (ITM) has proven to be excellent in reducing postoperative pain. However, its use has commonly been associated with the occurrence of postoperative nausea and vomiting (PONV). In recent years, the combination therapy of antiemetics comprising of a serotonin receptor antagonist and corticosteroid has been implemented to diminish the occurrence of PONV. Despite being routinely used, the evidence in the efficacy of this combination in parturients are conflicting and lacking. In this study, we wish to compare the efficacy between the combination therapy of granisetron plus dexamethasone versus granisetron alone on the occurrence of postoperative nausea and vomiting (PONV) in 126 parturients undergoing elective Caesarean delivery supplemented with intrathecal morphine.

Conditions

  • PONV

Interventions

DRUG

Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg

Comparing PONV incidences in both arms

DRUG

Granisetron 1 Mg/mL Intravenous Solution

Comparing PONV incidences in both arms

Sponsors & Collaborators

  • Universiti Sains Malaysia

    lead OTHER

Principal Investigators

  • Farah Nasuha Mohd Daut · Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-04-01
Completion
2021-06-01

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04570592 on ClinicalTrials.gov